Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Clinical Trials
1.1k
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1017 trials with phase data)• Click on a phase to view related trials
A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or Alpelisib
- Conditions
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Novartis
- Target Recruit Count
- 435
- Registration Number
- NCT06705504
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
- Conditions
- Heart Failure With Reduced Ejection FractionHeart Failure With Preserved Ejection Fraction
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 42494
- Registration Number
- NCT06671314
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell Centers
- Conditions
- Sickle Cell Disease
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 376
- Registration Number
- NCT06662825
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Characteristics and Treatment Patterns of Patients With Sickle Cell Disease in Globin Research Network for Data and Discovery Registry
- Conditions
- Sickle Cell Disease
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1665
- Registration Number
- NCT06662812
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Novartis
- Target Recruit Count
- 3632
- Registration Number
- NCT06644638
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 143
- Next
News
Novartis Secures Canadian Public Reimbursement for Cosentyx in Hidradenitis Suppurativa
Novartis successfully concluded negotiations with the pan-Canadian Pharmaceutical Alliance for public reimbursement of Cosentyx (secukinumab) to treat moderate to severe hidradenitis suppurativa.
Renasant Bio Raises $54.5M to Develop Novel Ion Channel Therapies for ADPKD
Renasant Bio secured $54.5 million in seed funding from investors including 5AM Ventures, Atlas Venture, OrbiMed and Qiming Venture Partners USA to develop treatments for autosomal dominant polycystic kidney disease (ADPKD).
Novartis Secures Exclusive Option for Sironax's Blood-Brain Barrier Platform in $175M Deal
Sironax has granted Novartis an exclusive option to acquire its proprietary Brain Delivery Module (BDM) platform, a differentiated blood-brain-barrier crossing technology designed to enhance brain delivery of therapeutics.
Novartis Receives Approval for First Malaria Treatment Designed for Newborns and Young Infants
Novartis has received Swiss regulatory approval for Coartem Baby, the first malaria treatment specifically formulated for newborns and infants weighing 2-5 kilograms.
Ascentage Pharma Strengthens Leadership Team with New CFO and Senior VP Appointments
Ascentage Pharma appointed Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance to support the company's global expansion strategy.
Monte Rosa's AI-Powered Discovery Engine Expands Molecular Glue Degrader Target Space in Science Publication
Monte Rosa Therapeutics published groundbreaking research on the cover of Science magazine, demonstrating how their AI and machine learning technologies have dramatically expanded the targetable protein space for molecular glue degraders.
Quebec Expands Public Reimbursement of Pluvicto Radioligand Therapy for Advanced Prostate Cancer
Quebec implemented public reimbursement of Pluvicto (lutetium-177 vipivotide tetraxetan) as of July 2, 2025, for eligible patients with PSMA-positive metastatic castration-resistant prostate cancer.
Novartis' Cosentyx Fails to Meet Primary Endpoint in Phase III Giant Cell Arteritis Trial
Novartis announced that its Phase III GCAptAIN study of Cosentyx (secukinumab) failed to achieve sustained remission at Week 52 in adults with newly diagnosed or relapsing giant cell arteritis.
House Republicans Subpoena Former Pfizer Executive Over Alleged COVID-19 Vaccine Trial Delays
House Judiciary Committee subpoenaed former Pfizer executive Dr. Philip Dormitzer over allegations that senior Pfizer executives deliberately slowed COVID-19 vaccine clinical testing before the 2020 election.
FDA Mandates New Safety Warnings for ADHD Stimulants in Children Under Six
The FDA is revising labeling for all extended-release ADHD stimulants to include warnings about weight loss and adverse reactions in children under six years old.